ANCHIANO THERAP/S (ANCN) Earns Outperform Rating from Analysts at Oppenheimer

Share on StockTwits

Oppenheimer began coverage on shares of ANCHIANO THERAP/S (NASDAQ:ANCN) in a report issued on Monday morning, The Fly reports. The brokerage issued an outperform rating and a $16.00 price objective on the stock.

Shares of ANCHIANO THERAP/S stock opened at $7.56 on Monday. ANCHIANO THERAP/S has a 52 week low of $7.33 and a 52 week high of $11.50.

About ANCHIANO THERAP/S

Anchiano Therapeutics Ltd, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to treat cancer-related diseases. It is primarily developing Inodiftagene vixteplasmid for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.

Read More: Trading Ex-Dividend Strategy

The Fly

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SkinCoin Trading Down 5.9% Over Last Week
SkinCoin Trading Down 5.9% Over Last Week
Bastonet  Tops One Day Volume of $84.00
Bastonet Tops One Day Volume of $84.00
Huncoin  Reaches 1-Day Volume of $63.00
Huncoin Reaches 1-Day Volume of $63.00
Cimarex Energy Co  Receives Consensus Rating of “Hold” from Brokerages
Cimarex Energy Co Receives Consensus Rating of “Hold” from Brokerages
Devon Energy Corp  Receives Average Rating of “Hold” from Brokerages
Devon Energy Corp Receives Average Rating of “Hold” from Brokerages
Analysts Set Amkor Technology, Inc.  Target Price at $7.00
Analysts Set Amkor Technology, Inc. Target Price at $7.00


 
© 2006-2019 Zolmax.